Ramat Gan, Israel

Ada Salman

This inventor holds 1 USPTO granted patent. Top assignee: Chemagis Ltd.. Active years: 2009.


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ada Salman: Innovator in Pharmaceutical Chemistry

Introduction

Ada Salman is a prominent inventor based in Ramat Gan, Israel. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel processes for drug formulation. Her work is characterized by a commitment to enhancing the purity and efficacy of pharmaceutical compounds.

Latest Patents

Ada Salman holds a patent for the "Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride." This invention provides a crystalline donepezil maleate, which serves as an intermediate in the preparation of donepezil hydrochloride. The patent also outlines innovative processes for producing the compound in substantially pure form, as well as a method for creating pharmaceutically pure amorphous donepezil hydrochloride from it. She has 1 patent to her name.

Career Highlights

Throughout her career, Ada has demonstrated exceptional expertise in pharmaceutical development. Her work at Chemagis Ltd. has positioned her as a key player in the industry, where she continues to push the boundaries of drug formulation and purity.

Collaborations

Ada collaborates with talented professionals in her field, including Oded Arad and Lior Zelikovitch. These partnerships enhance her research and contribute to the advancement of pharmaceutical innovations.

Conclusion

Ada Salman is a remarkable inventor whose contributions to pharmaceutical chemistry are noteworthy. Her dedication to improving drug formulations through innovative processes exemplifies her commitment to the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…